Basal insulins: Pharmacological properties and patient perspectives

Primary Care Diabetes

Volumn 4, Issue , 2010, Pages S19-S23

  Abrahamson, Martin J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Basal insulin; Control; Hypoglycaemia; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; INSULIN DETEMIR; ISOPHANE INSULIN;

CHEMICALLY INDUCED DISORDER; HUMAN; HYPOGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW;

DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, NPH;

MLCS; MLOWN;

EID: 77954942985     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/S1751-9918(10)60005-8     Document Type: Article

References (23)

1. Barnett, A., Dosing of insulin glargine in the treatment of type 2 diabetes. Clin. Ther. 29 (2007), 987–999.
2. Holman, R.R., Paul, S.K., Bethel, M.A., et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N. Engl. J Med. 359 (2008), 1577–1589.
3. UK Prospective Diabetes Study (UKPDS) Group, Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998), 837–853.
4. Home, P., The challenge of poorly controlled diabetes mellitus. Diabetes Metab. 29 (2003), 101–109.
5. Nathan, D.M., Buse, J.B., Davidson, M.B., et al. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 52 (2009), 17–30.
6. van Avendonk, M.J.P., Gorter, K.J., van den Donk, M., Rutten, G.E.H.M., Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands. Prim. Care Diabetes 3 (2009), 23–28.
7. Bazzano, L.A., Lee, L.J., Shi, L., et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet. Med. 25 (2008), 924–932.
8. Selam, J.-L., Koenen, C., Weng, W., Meneghini, L., Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr. Med. Res. Opin. 24 (2008), 11–20.
9. Riddle, M.C., Rosenstock, J., Gerich, J., on behalf of the INsulin Glargine 4002 Study Investigators, The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 26 (2003), 3080–3086.
10. Horvath, K., Jeitler, K., Berghold, A., et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst. Rev., 2007 CD005613.
11. Peyrot, M., Skovlund, S.E., Landgraf, R., Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. Curr. Med. Res. Opin. 25 (2009), 1985–1993.
12. Kurtzhals, P., How to achieve a predictable basal insulin?. Diabetes Metab., 31, 2005, 4S25 4S33.
13. Polonsky, K.S., Given, B.D., van Cauter, E., Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J. Clin. Invest. 81 (1988), 442–448.
14. Lepore, M., Pampanelli, S., Fanelli, C., et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 49 (2000), 2142–2148.
15. Scholtz, H.E., Pretorius, S.G., Wessels, D.H., Becker, R.H.A., Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia 48 (2005), 1988–1995.
16. Plank, J., Bodenlenz, M., Sinner, F., et al. A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir. Diabetes Care 28 (2005), 1107–1112.
17. Klein, O., Lynge, J., Endahl, L., et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes. Metab. 9 (2007), 290–299.
18. Philis-Tsimikas, A., Charpentier, G., Clauson, P., et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin. Ther. 28 (2006), 1569–1581.
19. Hermansen, K., Davies, M., Derezinski, T., et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naïve people with type 2 diabetes. Diabetes Care 29 (2006), 1269–1274.
20. Rosenstock, J., Davies, M., Home, P.D., et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 51 (2008), 408–416.
21. Meneghini, L., Koenen, C., Weng, W., Selam, J.-L., The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes – results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes. Metab. 9 (2007), 902–913.
22. Blonde, L., Merilainen, M., Karwe, V., et al. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets – the TITRATE™ study. Diabetes Obes. Metab. 11 (2009), 623–631.
23. Davies, M., Lavalle-González, F., Storms, F., Gomis, R., AT.LANTUS Study Group, Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. Diabetes Obes. Metab. 10 (2008), 387–399.